SCHEMBL19613828

SCHEMBL19613828

COc1ccc(CN(c2cccc(F)n2)S(=O)(=O)c2cc(C)c(NC3CCN(C(=O)O)C3)cc2F)c(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.38
KMT2A Q03164 3/20 0.38
MC4R P32245 2/20 0.38
MEN1 O00255 2/20 0.38
SCN1A P35498 3/20 0.36
SCN8A Q9UQD0 3/20 0.36
EGFR P00533 1/20 0.36
ITK Q08881 1/20 0.36
KCNH2 Q12809 1/20 0.35
GAA P10253 1/20 0.35
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HTT P42858 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19613826 1.00 RORC (0.38) RORCKMT2AMC4RMEN1SCN1A
SCHEMBL28532605 0.92 STS (0.40) RORCKMT2AMC4RMEN1ALDH1A1
SCHEMBL19631880 0.92 STS (0.40) RORCKMT2AMC4RMEN1ALDH1A1
SCHEMBL29447349 0.92 STS (0.40) RORCKMT2AMC4RMEN1ALDH1A1
SCHEMBL19614216 0.89 KMT2A (0.37) RORCKMT2AMC4RMEN1SCN1A
SCHEMBL19614215 0.89 KMT2A (0.37) RORCKMT2AMC4RMEN1SCN1A
SCHEMBL19614303 0.87 RORC (0.35) RORCKMT2AMC4RMEN1EGFR
SCHEMBL19614302 0.87 RORC (0.35) RORCKMT2AMC4RMEN1EGFR
SCHEMBL19627766 0.86 EPHX2 (0.38)
SCHEMBL19613877 0.85 SCN8A (0.45) RORCSCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 US disclosed
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-10-27 US disclosed
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-05-26 US disclosed
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2019-06-27 US disclosed
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2019-04-02 US disclosed
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B RORC 1292/4885KMT2A 2408/4885MC4R 3389/4885
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B RORC 1292/4885KMT2A 2408/4885MC4R 3389/4885
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B RORC 1292/4885KMT2A 2408/4885MC4R 3389/4885
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B RORC 1285/4885KMT2A 2494/4885MC4R 3372/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B RORC 1292/4885KMT2A 2408/4885MC4R 3389/4885
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B RORC 1285/4885KMT2A 2494/4885MC4R 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.